VahatiCor Inc

A newly published case report in JACC Journals highlights the potential of coronary sinus flow modulation using a novel self-expanding reducer to enhance coronary microvascular function in patients with persistent ischemia symptoms. Read the full case report here: https://lnkd.in/dDSRzDSQ It’s a timely addition to the growing conversation around coronary microvascular dysfunction (CMD), a space that remains underserved in interventional cardiology. A special thanks to Dr. Giovanni Occhipinti, Dr. Francesco Giannini, Dr. Rishi Puri, Dr. Omar Abdul-Jawad Altisent, Dr. Manel Sabate, and Dr. Salvatore Brugaletta for their continued leadership and contributions to the field. This work aligns closely with the mission we’re advancing at VahatiCor, a T45 Labs portfolio company. #CMD #MicrovascularDysfunction #Cardiology #InterventionalCardiology #JACC #Ischemia #VahatiCor #A-FLUX #reducertherapy

A recent study from the Netherlands confirms our longstanding position: invasive coronary function testing is essential for diagnosing Coronary Microvascular Dysfunction (CMD) in patients with angina and nonobstructive coronary arteries (ANOCA). As senior investigator Peter Damman, MD, PhD, stated, the study confirms that “testing can be done safely and that there is a high diagnostic yield when it is carried out.” Link to full article: https://lnkd.in/dkFJ5-Nv Key findings of the study have shown that: Invasive testing provides real answers. Patients left in diagnostic limbo are finally getting clear explanations for their symptoms. Safety is not a concern. Complications were minimal, reinforcing that invasive testing is both effective and low-risk. Spasm is the most common culprit. This highlights the need for functional testing and why standard imaging alone isn't enough. These results align with the 2024 European Society of Cardiology (ESC) guidelines: Invasive coronary function testing should be the next step when noninvasive tests fail. At VahatiCor, we're committed to shining a light on coronary microvascular dysfunction (CMD), bridging the diagnostic gap, and ensuring that more patients receive the answers and care they deserve. #VahatiCor #ShiningALight #CMD #HeartHealth #MicrovascularDysfunction #coronary #interventionalcardilogy #reducertherapy #Cardiology #CoronaryMicrovascularDysfunction #ANOCA #ESC2024 #FunctionalTesting #MedicalResearch #PatientCare

Chest pain? Sent home. Normal angiogram? Reassured, and still in pain. Serious cardiovascular risk? Missed. Overlooked. Ignored. ? Coronary Microvascular Dysfunction (CMD) is a silent epidemic in women. It is often overlooked on standard tests or fails to receive the attention it deserves, which for millions of women means going undiagnosed and untreated. At VahatiCor Inc, we believe it is time to change the narrative. We are here to shine a light on coronary microvascular dysfunction and give women the answers they deserve. Through research. Through awareness. Through improved treatment options. ? #InternationalWomensDay #IWD2024 #WomensHeartHealth #CMD #ShiningALight #VahatiCor #HeartHealth #CoronaryMicrovascularDysfunction #MicrovascularDisease

We’re thrilled to welcome Dr. Bruce Samuels to the VahatiCor Inc team! A renowned interventional cardiologist, educator, and leader in coronary microvascular dysfunction (CMD), Dr. Samuels brings decades of expertise and a passion for advancing cardiovascular care. As a founding member of the Microvascular Network, he has helped shape the global conversation on CMD diagnosis and treatment. His contributions to the Women's Ischemia Syndrome Evaluation (WISE) study and commitment to patient-centered innovation have made a lasting impact in both academia and clinical practice. Beyond his leadership in medical societies and editorial boards, Dr. Samuels is a respected mentor and advocate for expanding CMD awareness, ensuring overlooked patients receive the care they deserve. His ability to bridge cutting-edge research with real-world application aligns perfectly with our mission at Vahaticor. Join us in welcoming Dr. Bruce Samuels. We’re excited to see his leadership shape the future of cardiovascular care. #Vahaticor #Cardiology #MicrovascularDysfunction #CMD #InnovationInMedicine #HeartHealth #Leadership

Every year, 1 million patients in the US experience chronic angina due to dysfunction in their smallest coronary vessels—vessels thinner than two strands of hair.? Many of these patients are sent home without a clear diagnosis or effective treatment options despite facing a 5x increased risk of major adverse cardiac events (MACE) and a 4x higher mortality risk. At TCT 2024, Dr. Prof. maayan konigstein from Tel Aviv Medical Center presented findings from a single-arm prospective study evaluating coronary sinus reducer therapy in patients with angina and non-obstructive coronary artery disease (ANOCA). Key Study Outcomes: ?? Improved Microvascular Function Index of Microvascular Resistance (IMR) decreased from 39 to 17 Coronary Flow Reserve (CFR) improved from 1.7 to 2.9 ?? Significant Symptom Relief 74% of patients improved from severe angina (CCS Class 3 or 4) to less limiting classes ?? Better Quality of Life Patients showed meaningful gains in Seattle Angina Questionnaire (SAQ) scores and 6-minute walk test results Access the study details here: https://lnkd.in/d3qFERnA The takeaway? Reducer therapy works. It offers hope and life-changing results for patients suffering from coronary microvascular dysfunction (CMD), a condition that has long been overlooked in cardiovascular care. As we prepare to start our clinical trial for the A-FLUX Coronary Sinus Reducer, these findings reinforce the need to expand treatment options for CMD patients. #ANOCA #CoronaryMicrovascularDysfunction #CMD #MicrovascularDisease #SmallVessel #TCT2024 #CoronarySinusReducer #InterventionalCardiology #Angina #CMDResearch #ReducerTherapy

" Coronary Microvascular Dysfunction is found in 50% of the cases - if the operator looks for it." – Dr. Tim van de Hoef, Interventional Cardiologist, University Medical Center Utrecht In this interview, Dr. Tim Van De Hoef highlights the prevalence of Coronary Microvascular Dysfunction (CMD) and its challenges in clinical practice. CMD is under-recognized yet is a highly prevalent cause of angina pectoris. It is found in 50% of patients undergoing coronary angiography who don’t have obstructive coronary artery disease. There are few treatment options for these many patients with small vessel disease. The recent Class 1-B guidelines from the European Society of Cardiology will change CMD care. They strongly encourage coronary function testing for patients with angina despite medical therapy. More patients will be diagnosed. Dr. Tim van de Hoef also speaks about the potential of A-FLUX Coronary Sinus Reducer therapy: "New studies on the A-FLUX device will allow us to document its safety and efficacy, advancing dedicated treatment options for patients with CMD." The future of CMD care is taking shape, guided by innovation, clinical evidence and the insights of experts like Dr. Van De Hoef. Watch the full interview below to learn more about CMD, the impact of ESC guidelines, and the promise of innovative reducer therapies. ? #CMD #CoronaryMicrovascularDysfunction #InterventionalCardiology #ESCGuidelines #CardiologyCare #Innovation #PatientCare #HeartHealth #WomenInCardiology #CardiovascularResearch #AFLUXReducer #CoronaryFunctionTesting #ClinicalPractice

This holiday season, we continue our mission to champion those living with coronary microvascular dysfunction, a condition affecting millions yet often overlooked. Our work remains focused on turning awareness into action. From supporting critical research to amplifying patient voices, we're committed to making CMD a recognized and treatable condition. We all at VahatiCor Inc wish you a joyful holiday season filled with warmth, health, and hope. Here's to a new year of meaningful progress and shared success. Merry Christmas and Happy Holidays! #ThankYou #HappyHolidays #Christmas2024 #HappyNewYear #CMD #VahatiCor #AFluxReducer

"My wish for CMD patients? That they no longer need to see us at the hospital. Instead, I'd love to meet them outside, having a cup of wine or a beer together." – Dr. Manel Sabate, Hospital Clínic de Barcelona ? Coronary Microvascular Dysfunction (CMD), a problem in the smallest vessels of the heart, often leaves patients without options and physicians without solutions. ? In an insightful interview, Dr. Manel Sabate, Head of Interventional Cardiology at Hospital Clínic de Barcelona, shares his experience with the A-FLUX Coronary Sinus Reducer. ? Dr. Sabaté sees hope where patients once saw none. For microvascular patients, reducer therapy could mean a step toward reclaiming their quality of life. ? Insights like these encourage us to help these patients as we prepare to start our clinical trial for the next generation A-FLUX Coronary Sinus Reducer. ? #CoronaryMicrovascularDysfunction #CMD #AFLUXReducer #InterventionalCardiology #CardiologyInnovation #PatientFirst #VahatiCor

This year, 1 million patients with chest pain and a problem in the small vessels of their heart, vessels that are thinner than 2 strands of hair, will be sent home with no diagnosis and no treatment in the US and the EU. Patients with small vessel dysfunction are at higher risk of death and a major adverse cardiac event. Physicians from the Mayo Clinic and the University of Arizona College of Medicine recently demonstrated that well-selected patients with coronary microvascular dysfunction benefited from reducer therapy – the controlled narrowing of a large vein in the heart. Their patients averaged 55 years of age and were primarily women (67%). Reducer therapy improved both their symptoms and the ability of their heart to pump more blood during effort. Read the complete study here: https://lnkd.in/ddDZ4xUw This study encourages us to help these patients as we prepare to start our clinical trial for the next generation A-FLUX Coronary Sinus Reducer. The emergence of an effective therapy will likely encourage more physicians to diagnose and help these many patients. #CoronaryMicrovascularDysfunction #Reducertherapy #angina #coronarysinusreducer #interventionalcardiology #clinicalstudy #CMD #coronarysinus #inoca #smallvessel #microvascular